Eris Lifesciences Limited (NSE: ERIS)
India
· Delayed Price · Currency is INR | Market Cap | 197.11B |
| Revenue (ttm) | 22.47B |
| Net Income (ttm) | 3.80B |
| Shares Out | 136.08M |
| EPS (ttm) | 27.92 |
| PE Ratio | 51.88 |
| Forward PE | 45.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 506,639 |
| Open | 1,469.00 |
| Previous Close | 1,459.85 |
| Day's Range | 1,427.20 - 1,522.05 |
| 52-Week Range | 792.35 - 1,522.05 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Eris Lifesciences
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measureme... [Read more]
Financial Performance
In 2023, ERIS's revenue was 19.91 billion, an increase of 19.83% compared to the previous year's 16.62 billion. Earnings were 3.92 billion, an increase of 2.57%.
Financial StatementsNews
ChrysCapital sells entire stake in Eris Lifesciences for ₹1,187 Crore
Private equity firm ChrysCapital has exited its investment in Eris Lifesciences by selling its entire 7.27% stake in the company for ₹1,187 crore. The stake was purchased by Infinity Partners through ...
Eris Lifesciences sees 7.2% equity change hands in ₹1,187 crore block deal
Eris Lifesciences witnessed a substantial block deal on August 22, with approximately 98.9 lakh shares, representing 7.27% of its equity, changing hands for ₹1,201 per share, totaling ₹1,187 crore. De...